Cassava Sciences Inc (SAVA) Stock Analysis

Cassava Sciences Inc (SAVA) is a publicly traded company in the HEALTHCARE sector. It trades at $2.38, carries a market capitalization of $114.97M. This page summarizes the public market data, fundamentals, and frequently asked questions for SAVA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cassava Sciences Inc currently has a Bearish sentiment score of -0.15.

About Cassava Sciences Inc

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, dedicated to pioneering innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company is advancing its lead candidate, simufilam, through late-stage clinical trials to establish its potential effectiveness and safety. By addressing critical unmet medical needs in neurology, Cassava aims to transform the treatment landscape for neurodegenerative disorders, po...

GNG Research Analysis

GNG Research scores Cassava Sciences Inc (SAVA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SAVA.

Frequently Asked Questions

Does SAVA pay dividends?

Cassava Sciences Inc (SAVA) does not currently pay a regular dividend.

What is SAVA's market cap?

Cassava Sciences Inc (SAVA) has a market capitalization of $114.97M with a current stock price of $2.38.